Skip to main content

4 Result(s)

within Seiichiro Katagiri Remove this filter

and

  1. No Access

    Article

    Maintenance 5-azacytidine therapy by MRD monitoring after allogeneic HSCT in myeloid/lymphoid neoplasms with FGFR1 rearrangement

    Seiichiro Katagiri, Tomohiro Umezu, Kenko Azuma… in Bone Marrow Transplantation (2019)

  2. No Access

    Article

    Up-regulated exosomal miRNA-140-3p in CML patients with musculoskeletal pain associated with discontinuation of tyrosine kinase inhibitors

    We analyzed the exosomal miRNA from peripheral blood from CML patients with musculoskeletal pain after stop** tyrosine kinase inhibitors to identify possible factors related to this manifestation. Exosomal m...

    Michiyo Asano, Tomohiro Umezu, Seiichiro Katagiri… in International Journal of Hematology (2017)

  3. No Access

    Article

    Fatal Cyberlindnera fabianii fungemia in a patient with mixed phenotype acute leukemia after umbilical cord blood transplantation

    We report a case of Cyberlindnera fabianii fungemia after umbilical cord blood transplantation (CBT). A 69-year-old woman was diagnosed as having mixed phenotype acute leukemia. The patient received CBT for prima...

    Seiichiro Katagiri, Moritaka Gotoh, Kazuya Tone… in International Journal of Hematology (2016)

  4. Article

    Open Access

    Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells

    The ABL kinase inhibitor imatinib is highly effective in treating most, but not all, patients with chronic myeloid leukemia (CML). This is because residual CML cells are generally present in the bone marrow mi...

    Seiichi Okabe, Tetsuzo Tauchi, Seiichiro Katagiri… in Journal of Hematology & Oncology (2014)

    Download PDF (1528 KB) View Article